Today, CureDuchenne announced a $1 million investment in Capricor Therapeutics for a clinical trial to test its CDC (adult) stem cells as a cardiac therapy for Duchenne patients.
CureDuchenne’s mission is our name…to cure Duchenne. Duchenne affects so many parts of the body and cardiac failure is the primary cause of death in this disease. CureDuchenne is dedicated to treating the whole disease and cardiac care and treatments are an integral part of our strategy.
A special acknowledgment to Cath Jayasuiya and Coalition Duchenne for their early and continued work with Dr. Eduardo Marbán and Capricor. Overcoming the primary cause of death in Duchenne patients is daunting and we look forward to working together to see this therapy advance as quickly as possible.
To learn more, go to www.CureDuchenne.org/Capricor.
We’ll be hosting a webinar with Capricor on Wednesday, January 21 at 3:00 p.m. ET and noon PT to discuss the research. Register for webinar. The call in number is (844) 337-8088 and the conference id number is: 65477372.
Click to donate to this research project.